p300 Acetyltransferase Is a Cytoplasm‐to‐Nucleus Shuttle for SMAD2/3 and TAZ Nuclear Transport in Transforming Growth Factor β–Stimulated Hepatic Stellate Cells

Yuanguo Wang, Kangsheng Tu, Donglian Liu, Luyang Guo, Yunru Chen, Qing Li, Jessica L. Maiers, Zhikui Liu, Vijay H. Shah, Changwei Dou, Daniel Tschumperlin, Luke Voneschen, Rendong Yang, Ningling Kang – 20 April 2019 – Nuclear translocation of mothers against decapentaplegic homolog 2/3 (SMAD2/3), core transcription factors of transforming growth factor β (TGF‐β) signaling, is critical for hepatic stellate cell (HSC) differentiation into metastasis‐promoting myofibroblasts.

External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of Renal Recovery After Liver Transplantation

Josh Levitsky, Sumeet K. Asrani, Michael Abecassis, Richard Ruiz, Linda W. Jennings, Goran Klintmalm – 19 April 2019 – In patients with end‐stage liver disease, the ability to predict recovery of renal function following liver transplantation (LT) remains elusive. However, several important clinical decisions depend on whether renal dysfunction is recoverable after LT.

Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma

Carina Hage, Sabine Hoves, Léanne Strauss, Stefan Bissinger, Ylva Prinz, Thomas Pöschinger, Fabian Kiessling, Carola H. Ries – 19 April 2019 – Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). We report that sorafenib also acts through direct immune modulation, indispensable for its antitumor activity.

Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes

Llilda Barata, Mary F. Feitosa, Lawrence F. Bielak, Brian Halligan, Abigail S. Baldridge, Xiuqing Guo, Laura M. Yerges‐Armstrong, Albert V. Smith, Jie Yao, Nicholette D. Palmer, Lisa B. VanWagner, J. Jeffrey Carr, Yii‐Der I. Chen, Matthew Allison, Matthew J. Budoff, Samuel K. Handelman, Sharon L.R. Kardia, Thomas H. Mosley, Kathleen Ryan, Tamara B. Harris, Lenore J. Launer, Vilmundur Gudnason, Jerome I. Rotter, Myriam Fornage, Laura J. Rasmussen‐Torvik, Ingrid B. Borecki, Jeffrey R. O’Connell, Patricia A. Peyser, Elizabeth K. Speliotes, Michael A.

Nocturnal Hypoxia Activation of the Hedgehog Signaling Pathway Affects Pediatric Nonalcoholic Fatty Liver Disease Severity

Shikha S. Sundaram, Marzena Swiderska‐Syn, Ronald J. Sokol, Ann C. Halbower, Kelley E. Capocelli, Zhaoxing Pan, Kristen Robbins, Brian Graham, Anna Mae Diehl – 17 April 2019 – Chronic intermittent hypoxia and hedgehog (Hh) pathway dysregulation are associated with nonalcoholic fatty liver disease (NAFLD) progression. In this study, we determined the relationship between obstructive sleep apnea (OSA)/nocturnal hypoxia and Hh signaling in pediatric NAFLD.

Subscribe to